These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 6861123

  • 1. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.
    Celik C, Lewis DA, Goldrosen MH.
    Cancer Res; 1983 Aug; 43(8):3507-10. PubMed ID: 6861123
    [Abstract] [Full Text] [Related]

  • 2. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC, Abrams JT, Zhang SY, Galili U.
    Cancer Res; 1999 Jul 15; 59(14):3417-23. PubMed ID: 10416604
    [Abstract] [Full Text] [Related]

  • 3. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
    Stackpole CW, Demsey A.
    Invasion Metastasis; 1984 Jul 15; 4(1):28-46. PubMed ID: 6329988
    [Abstract] [Full Text] [Related]

  • 4. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
    Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG.
    Cancer Res; 1999 Jun 15; 59(12):2802-5. PubMed ID: 10383135
    [Abstract] [Full Text] [Related]

  • 5. Increased immunogenicity of B16 melanoma clones selected for their ability to metastasize from a heterogeneous primary tumor.
    Steele GD, Richie JP, Wang BS, Mannick JA, Wilson RE.
    Surg Forum; 1979 Jun 15; 30():132-3. PubMed ID: 538574
    [No Abstract] [Full Text] [Related]

  • 6. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors.
    Baniyash M, Smorodinsky NI, Yaakubovicz M, Witz IP.
    J Immunol; 1982 Sep 15; 129(3):1318-23. PubMed ID: 7108209
    [Abstract] [Full Text] [Related]

  • 7. Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors.
    Flood PM, Schreiber H, Ron Y.
    J Immunol; 1987 May 15; 138(10):3573-9. PubMed ID: 3571978
    [Abstract] [Full Text] [Related]

  • 8. Identification of immunogenic B16 melanoma-associated antigens.
    Johnston D, Schachne JP, Bystryn JC.
    J Biol Response Mod; 1987 Apr 15; 6(2):108-20. PubMed ID: 3585408
    [Abstract] [Full Text] [Related]

  • 9. A role for mast cells and the vasoactive amine serotonin in T cell-dependent immunity to tumors.
    Van Loveren H, Den Otter W, Meade R, Terheggen PM, Askenase PW.
    J Immunol; 1985 Feb 15; 134(2):1292-9. PubMed ID: 3871209
    [Abstract] [Full Text] [Related]

  • 10. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O, Dohlsten M, Sjögren HO.
    Cancer Gene Ther; 2000 Oct 15; 7(10):1365-74. PubMed ID: 11059695
    [Abstract] [Full Text] [Related]

  • 11. [Immunogenicity of 2 murine B16 melanoma variants with high metastatic potential].
    Hosni M, Santini R, Deschaux P, Pacheco H.
    C R Seances Soc Biol Fil; 1990 Oct 15; 184(1):47-54. PubMed ID: 2150781
    [Abstract] [Full Text] [Related]

  • 12. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J, Saffold S, Cao X, Krauss J, Chen W.
    J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.
    J Gene Med; 1999 Nov 15; 1(6):400-6. PubMed ID: 10753065
    [Abstract] [Full Text] [Related]

  • 14. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP, Bogaars H, Wolf SF, Hearing VJ, Wanebo HJ.
    Int J Oncol; 1998 Aug 15; 13(2):361-74. PubMed ID: 9664134
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
    Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S.
    Cancer Res; 2000 Oct 01; 60(19):5514-21. PubMed ID: 11034096
    [Abstract] [Full Text] [Related]

  • 16. [Cytotoxic immunity indices of melanoma B16 growth in mice].
    Korosteleva TA, Veresova OV.
    Vopr Onkol; 1980 Oct 01; 26(1):67-70. PubMed ID: 7355591
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and tumor protective activity of B16 melanoma vaccines.
    Johnston D, Bystryn JC.
    Mol Biother; 1989 Oct 01; 1(4):218-22. PubMed ID: 2818873
    [Abstract] [Full Text] [Related]

  • 18. Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens.
    Bystryn JC.
    J Immunol; 1978 Jan 01; 120(1):96-101. PubMed ID: 627729
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C.
    Cancer Res; 2006 Jun 15; 66(12):6395-404. PubMed ID: 16778218
    [Abstract] [Full Text] [Related]

  • 20. Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma.
    Fidler IJ, Nicolson GL.
    Isr J Med Sci; 1978 Jan 15; 14(1):38-50. PubMed ID: 632082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.